Corifollitropin Alfa

Summary

Corifollitropin Alfa (CHEMBL2108185) is an approved protein (ATC G03GA09); indicated across 6 conditions including infertility disorder and hypogonadism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: G03GA09
• Indications: 6 conditions
• Clinical trials: 42

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108185
Name	Corifollitropin Alfa
Type	Protein
Max phase	4
ATC	G03GA09

Also known as: Corifolitropina alfa, Corifollitropin alfa, Corifollitropine alfa, Elonva, MK-8962, ORG 36286, ORG-36286, SCH 900962, SCH-900962, CORIFOLLITROPIN ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infertility disorder	3	MONDO:0005047	EFO:0000545
hypogonadism	3	MONDO:0002146	MONDO:0018555

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE4	14
Not specified	11
PHASE3	9
PHASE2	6
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01633580	PHASE4	COMPLETED	D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists
NCT02046655	PHASE4	COMPLETED	Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI
NCT02213627	PHASE4	UNKNOWN	Use of Corifolitropin Alfa in Oocyte Donors
NCT02215135	PHASE4	UNKNOWN	Corifollitropin Alfa Application in PCOS Patients
NCT02254928	PHASE4	TERMINATED	Corifollitropin Alfa Versus Daily rFSH in the Controlled Ovarian Stimulation of Poor Responders
NCT02402192	PHASE4	TERMINATED	Type of Gonadotropin and Embryo Kinetics of Development
NCT02466204	PHASE4	COMPLETED	Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients
NCT02471677	PHASE4	UNKNOWN	Corifollitropin Alfa Versus Follitropin Beta in High Responders
NCT02490150	PHASE4	COMPLETED	Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill
NCT02606500	PHASE4	COMPLETED	Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success
NCT03177538	PHASE4	COMPLETED	Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
NCT03208972	PHASE4	COMPLETED	Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG
NCT04695483	PHASE4	COMPLETED	Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial
NCT05815719	PHASE4	COMPLETED	Continuous Double Ovarian Stimulation.
NCT00696800	PHASE3	COMPLETED	A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
NCT00696878	PHASE3	COMPLETED	Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)
NCT01144416	PHASE3	COMPLETED	Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
NCT01146418	PHASE3	COMPLETED	Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)
NCT01599494	PHASE3	WITHDRAWN	An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
NCT01709331	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
NCT01816321	PHASE3	COMPLETED	Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
NCT03019575	PHASE3	COMPLETED	Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
NCT03197077	PHASE3	COMPLETED	Optimisation of Follicular Recruitment in IVM Cycles
NCT00598208	PHASE2	COMPLETED	A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)
NCT00697255	PHASE2	TERMINATED	A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)
NCT00702585	PHASE2	COMPLETED	Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)
NCT00702806	PHASE2	COMPLETED	Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)
NCT01319695	PHASE1/PHASE2	COMPLETED	Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation
NCT01732068	PHASE2	COMPLETED	Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol
NCT01732094	PHASE2	COMPLETED	Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders
NCT00647933	PHASE1	COMPLETED	An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)
NCT00702234	Not specified	COMPLETED	Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)
NCT00702338	Not specified	COMPLETED	Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
NCT00702546	Not specified	COMPLETED	Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)
NCT00702624	Not specified	COMPLETED	Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)
NCT00702988	Not specified	COMPLETED	Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)
NCT00703014	Not specified	COMPLETED	Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
NCT01408615	Not specified	COMPLETED	A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
NCT03816670	Not specified	COMPLETED	Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF
NCT04142190	Not specified	COMPLETED	Corifollitropin Alfa and Embryo Morphokinetics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).